• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sanofi starts first clinical trial of H7N1 vaccine

AlaskaDenise

In Memoriam
Pour les English....

http://news.xinhuanet.com/english/2006-09/20/content_5112567.htm

PARIS, Sept. 19 (Xinhua) -- Sanofi Pasteur, the vaccines business of the sanofi-Aventis Group, has started the first clinical trial of a new generation of H7N1 pandemic vaccine to fight against bird flu, the company announced Tuesday in a statement.


"The trial with the vaccine would expand the Sanofi Pasteur's preparation to the flu pandemic, which is initiated with the development of H5N1 vaccine," the statement said.

The company also said that while most vaccine development has focused on H5N1 strains, the H7 avian viruses remain a significant pandemic threat.

The trial is the first to assess the safety and ability to generate an immune response of a split, inactivated prototype pandemic H7N1 vaccine produced on cells, Sanofi said.
This phase I clinical trail is conducted in a project of Flupan, a European Union (EU) funded collaboration, and financed by EU. Initiated on Tuesday in Bergen, Norway, the trial is intended to improve the level of pandemic preparation in EU countries.

.
 
Back
Top